Literature DB >> 8254852

Hepatitis B vaccine responsiveness in Connecticut public safety personnel.

A J Roome1, S J Walsh, M L Cartter, J L Hadler.   

Abstract

OBJECTIVE: To determine the level and determinants of vaccine response in recently inoculated public safety personnel.
DESIGN: Prevalence survey. PARTICIPANTS: Public safety personnel who had completed vaccination 1 to 6 months prior to testing and had no serological evidence of previous exposure to hepatitis B virus. MAIN OUTCOME MEASURE: An inadequate level of antibody to hepatitis B surface antigen was defined as less than 10 mlU/mL.
RESULTS: All subjects in the study had been vaccinated using Recombivax HB, a recombinant hepatitis B vaccine. Of 528 individuals, 11.9% were found to have no or inadequate levels of antibody. The frequency of inadequate level of antibody increased significantly relative to age, from 2.8% among those younger than 30 years to 42.1% among those older than 60 years (P < .0001). Smoking (odds ratio [OR], 3.6; 95% confidence interval [CI], 2.0 to 6.4), extreme obesity (OR, 13.3; 95% CI, 3.8 to 49.1), and increasing time interval since completing the vaccine series (P < .01) were also associated with inadequate levels of antibody. These findings were confirmed by multivariate analysis using logistic regression.
CONCLUSIONS: Routine immunization of public safety personnel should include selective use of postvaccine testing. Postvaccination testing optimally should be performed in the 30- to 90-day interval after the last vaccine dose. New vaccination strategies are needed to improve response rates in persons with predictably poor response to hepatitis B vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8254852

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  37 in total

1.  Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Authors:  Celine A Hayden; Stephen J Streatfield; Barry J Lamphear; Gina M Fake; Todd K Keener; John H Walker; John D Clements; Debra D Turner; Ian R Tizard; John A Howard
Journal:  Vaccine       Date:  2012-03-08       Impact factor: 3.641

2.  Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination.

Authors:  Ru-Xiang Wang; Greet J Boland; Jan van Hattum; Gijsbert C de Gast
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

Review 3.  Post-exposure prophylaxis for blood borne viral infections in healthcare workers.

Authors:  G M Varghese; O C Abraham; D Mathai
Journal:  Postgrad Med J       Date:  2003-06       Impact factor: 2.401

4.  Pigeon fanciers' lung: effects of smoking on serum and salivary antibody responses to pigeon antigens.

Authors:  C I Baldwin; A Todd; S Bourke; A Allen; J E Calvert
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 5.  Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow.

Authors:  Giovanna Vitaliti; Andrea Domenico Praticò; Carla Cimino; Giovanna Di Dio; Elena Lionetti; Mario La Rosa; Salvatore Leonardi
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 6.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

7.  Production of highly concentrated, heat-stable hepatitis B surface antigen in maize.

Authors:  Celine A Hayden; Erin M Egelkrout; Alessa M Moscoso; Cristina Enrique; Todd K Keener; Rafael Jimenez-Flores; Jeffrey C Wong; John A Howard
Journal:  Plant Biotechnol J       Date:  2012-07-21       Impact factor: 9.803

8.  Sleep and antibody response to hepatitis B vaccination.

Authors:  Aric A Prather; Martica Hall; Jacqueline M Fury; Diana C Ross; Matthew F Muldoon; Sheldon Cohen; Anna L Marsland
Journal:  Sleep       Date:  2012-08-01       Impact factor: 5.849

9.  Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis.

Authors:  Erik Seth Kramer; Charlotte Hofmann; Paula G Smith; Mitchell L Shiffman; Richard K Sterling
Journal:  Dig Dis Sci       Date:  2009-06-11       Impact factor: 3.199

Review 10.  Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination.

Authors:  Rudruidee Karnchanasorn; Horng-Yih Ou; James Lin; Lee-Ming Chuang; Ken C Chiu
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.